HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and α4β7 on CD4 T-Cells Prior Therapy Initiation.

dc.contributor.authorRosado-Sánchez, Isaac
dc.contributor.authorHerrero-Fernández, Inés
dc.contributor.authorGenebat, Miguel
dc.contributor.authorDel Romero, Jorge
dc.contributor.authorRiera, Melchor
dc.contributor.authorPodzamczer, Daniel
dc.contributor.authorOlalla, Julián
dc.contributor.authorVidal, Francesc
dc.contributor.authorMuñoz-Fernández, Mª Angeles
dc.contributor.authorLeal, Manuel
dc.contributor.authorPacheco, Yolanda M
dc.date.accessioned2025-01-07T16:38:27Z
dc.date.available2025-01-07T16:38:27Z
dc.date.issued2018-07-18
dc.description.abstractHIV-infected subjects with suboptimal CD4 restoration despite suppressive combined antiretroviral treatment (cART) (immunodiscordant subjects) have been classically characterized after a variable period of time under cART. Recently, we have reported that an increased frequency of proliferating CD4 T-cells in these subjects is already present before the cART onset. The potential contribution of peripheral compensatory homeostatic proliferation (HP) is yet unknown. We aimed to analyze the expression of HP-related cellular markers on CD4 T-cells of immunodiscordant subjects before cART. We analyzed the expression of OX40 and α4β7 on peripheral CD4 T-cells from immunodiscordant and control subjects (n = 21 each group) before cART initiation, and also on available follow-up samples (after 24 month of suppressive cART). Additionally, we tested the expression of these markers in an in vitro system for the study of human HP processes. Immunodiscordant subjects showed increased levels of OX40 and α4β7 on CD4 T-cells before cART initiation. While the cART tended to reduce these levels, immunodiscordant subjects still maintained comparatively higher levels of OX40 and α4β7 after 24 months under suppressive cART. These HP-related markers were upregulated in vitro during the human HP, especially during the fast HP. Our results are compatible with exacerbated HP processes in immunodiscordant subjects, already before the cART onset.
dc.identifier.doi10.3389/fimmu.2018.01673
dc.identifier.issn1664-3224
dc.identifier.pmcPMC6058017
dc.identifier.pmid30073002
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC6058017/pdf
dc.identifier.unpaywallURLhttps://www.frontiersin.org/articles/10.3389/fimmu.2018.01673/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27913
dc.journal.titleFrontiers in immunology
dc.journal.titleabbreviationFront Immunol
dc.language.isoen
dc.organizationInstituto de Investigación Biomédica de Sevilla (IBIS)
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.organizationSAS - Hospital Costa del Sol
dc.organizationInstituto de Investigación Biomédica de Sevilla (IBIS)
dc.page.number1673
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCD4 T-cell homeostasis
dc.subjectHIV
dc.subjectOX40
dc.subjecthomeostatic parameters
dc.subjecthomeostatic proliferation
dc.subjectimmunodiscordant response to combined antiretroviral treatment
dc.subjectlow CD4 recovery
dc.subjectα4β7
dc.titleHIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and α4β7 on CD4 T-Cells Prior Therapy Initiation.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number9

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC6058017.pdf
Size:
1.26 MB
Format:
Adobe Portable Document Format